IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-35815-7.html
   My bibliography  Save this article

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Author

Listed:
  • Hung Fu Tseng

    (Kaiser Permanente Southern California
    Kaiser Permanente Bernard J. Tyson School of Medicine)

  • Bradley K. Ackerson

    (Kaiser Permanente Southern California)

  • Katia J. Bruxvoort

    (Kaiser Permanente Southern California
    University of Alabama at Birmingham)

  • Lina S. Sy

    (Kaiser Permanente Southern California)

  • Julia E. Tubert

    (Kaiser Permanente Southern California)

  • Gina S. Lee

    (Kaiser Permanente Southern California)

  • Jennifer H. Ku

    (Kaiser Permanente Southern California)

  • Ana Florea

    (Kaiser Permanente Southern California)

  • Yi Luo

    (Kaiser Permanente Southern California)

  • Sijia Qiu

    (Kaiser Permanente Southern California)

  • Soon Kyu Choi

    (Kaiser Permanente Southern California)

  • Harpreet S. Takhar

    (Kaiser Permanente Southern California)

  • Michael Aragones

    (Kaiser Permanente Southern California)

  • Yamuna D. Paila

    (Moderna, Inc.)

  • Scott Chavers

    (Moderna, Inc.)

  • Carla A. Talarico

    (Moderna, Inc.
    AstraZeneca)

  • Lei Qian

    (Kaiser Permanente Southern California)

Abstract

Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against omicron BA.4/BA.5 compared with earlier omicron subvariants. This test-negative case–control study evaluates mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with omicron subvariants. The study includes 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection is high and wanes slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection is initially moderate to high (61.0%-90.6% 14-30 days post third dose) and wanes rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranges between 64.3%-75.7%, and is low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 is 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 is 88.5%. Evaluation of the updated bivalent booster is warranted.

Suggested Citation

  • Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-35815-7
    DOI: 10.1038/s41467-023-35815-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-35815-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-35815-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yunlong Cao & Ayijiang Yisimayi & Fanchong Jian & Weiliang Song & Tianhe Xiao & Lei Wang & Shuo Du & Jing Wang & Qianqian Li & Xiaosu Chen & Yuanling Yu & Peng Wang & Zhiying Zhang & Pulan Liu & Ran A, 2022. "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection," Nature, Nature, vol. 608(7923), pages 593-602, August.
    2. Julia Stowe & Nick Andrews & Freja Kirsebom & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    3. Raquel Viana & Sikhulile Moyo & Daniel G. Amoako & Houriiyah Tegally & Cathrine Scheepers & Christian L. Althaus & Ugochukwu J. Anyaneji & Phillip A. Bester & Maciej F. Boni & Mohammed Chand & Wonderf, 2022. "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa," Nature, Nature, vol. 603(7902), pages 679-686, March.
    4. Qian Wang & Yicheng Guo & Sho Iketani & Manoj S. Nair & Zhiteng Li & Hiroshi Mohri & Maple Wang & Jian Yu & Anthony D. Bowen & Jennifer Y. Chang & Jayesh G. Shah & Nadia Nguyen & Zhiwei Chen & Kathrin, 2022. "Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5," Nature, Nature, vol. 608(7923), pages 603-608, August.
    5. Hiam Chemaitelly & Houssein H. Ayoub & Sawsan AlMukdad & Peter Coyle & Patrick Tang & Hadi M. Yassine & Hebah A. Al-Khatib & Maria K. Smatti & Mohammad R. Hasan & Zaina Al-Kanaani & Einas Al-Kuwari & , 2022. "Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Guoli Shi & Tiansheng Li & Kin Kui Lai & Reed F. Johnson & Jonathan W. Yewdell & Alex A. Compton, 2024. "Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Joseph A. Lewnard & Vennis Hong & Jeniffer S. Kim & Sally F. Shaw & Bruno Lewin & Harpreet Takhar & Sara Y. Tartof, 2023. "Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    3. Zhennan Zhao & Yufeng Xie & Bin Bai & Chunliang Luo & Jingya Zhou & Weiwei Li & Yumin Meng & Linjie Li & Dedong Li & Xiaomei Li & Xiaoxiong Li & Xiaoyun Wang & Junqing Sun & Zepeng Xu & Yeping Sun & W, 2023. "Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    4. Saya Moriyama & Yuki Anraku & Shunta Taminishi & Yu Adachi & Daisuke Kuroda & Shunsuke Kita & Yusuke Higuchi & Yuhei Kirita & Ryutaro Kotaki & Keisuke Tonouchi & Kohei Yumoto & Tateki Suzuki & Taiyou , 2023. "Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    5. Laura Solforosi & Lea M. M. Costes & Jeroen T. B. M. Tolboom & Katherine McMahan & Tochi Anioke & David Hope & Tetyana Murdza & Michaela Sciacca & Emily Bouffard & Julia Barrett & Cindy Wu & Nicole Ha, 2023. "Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    6. Taha Y. Taha & Irene P. Chen & Jennifer M. Hayashi & Takako Tabata & Keith Walcott & Gabriella R. Kimmerly & Abdullah M. Syed & Alison Ciling & Rahul K. Suryawanshi & Hannah S. Martin & Bryan H. Bach , 2023. "Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    7. Alvin X. Han & Emma Hannay & Sergio Carmona & Bill Rodriguez & Brooke E. Nichols & Colin A. Russell, 2023. "Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    8. Joseph A. Lewnard & Vennis Hong & Jeniffer S. Kim & Sally F. Shaw & Bruno Lewin & Harpreet Takhar & Marc Lipsitch & Sara Y. Tartof, 2023. "Increased vaccine sensitivity of an emerging SARS-CoV-2 variant," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    9. X. Tong & R. P. McNamara & M. J. Avendaño & E. F. Serrano & T. García-Salum & C. Pardo-Roa & H. L. Bertera & T. M. Chicz & J. Levican & E. Poblete & E. Salinas & A. Muñoz & A. Riquelme & G. Alter & R., 2023. "Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    10. Dapeng Li & David R. Martinez & Alexandra Schäfer & Haiyan Chen & Maggie Barr & Laura L. Sutherland & Esther Lee & Robert Parks & Dieter Mielke & Whitney Edwards & Amanda Newman & Kevin W. Bock & Mahn, 2022. "Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    11. Felix Dewald & Martin Pirkl & Martha Paluschinski & Joachim Kühn & Carina Elsner & Bianca Schulte & Jacqueline Knüfer & Elvin Ahmadov & Maike Schlotz & Göksu Oral & Michael Bernhard & Mark Michael & M, 2023. "Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    12. Meriem Bekliz & Kenneth Adea & Pauline Vetter & Christiane S. Eberhardt & Krisztina Hosszu-Fellous & Diem-Lan Vu & Olha Puhach & Manel Essaidi-Laziosi & Sophie Waldvogel-Abramowski & Caroline Stephan , 2022. "Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    13. Sapna Sharma & Thomas Vercruysse & Lorena Sanchez-Felipe & Winnie Kerstens & Madina Rasulova & Lindsey Bervoets & Carolien Keyzer & Rana Abdelnabi & Caroline S. Foo & Viktor Lemmens & Dominique Loover, 2022. "Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    14. Emanuele Andreano & Ida Paciello & Silvia Marchese & Lorena Donnici & Giulio Pierleoni & Giulia Piccini & Noemi Manganaro & Elisa Pantano & Valentina Abbiento & Piero Pileri & Linda Benincasa & Ginevr, 2022. "Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    15. Kaiyuan Sun & Stefano Tempia & Jackie Kleynhans & Anne Gottberg & Meredith L. McMorrow & Nicole Wolter & Jinal N. Bhiman & Jocelyn Moyes & Maimuna Carrim & Neil A. Martinson & Kathleen Kahn & Limakats, 2023. "Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    16. Haofeng Wang & Qi Yang & Xiaoce Liu & Zili Xu & Maolin Shao & Dongxu Li & Yinkai Duan & Jielin Tang & Xianqiang Yu & Yumin Zhang & Aihua Hao & Yajie Wang & Jie Chen & Chenghao Zhu & Luke Guddat & Hong, 2023. "Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    17. Xiaolei Wang & Terrence Tsz-Tai Yuen & Ying Dou & Jingchu Hu & Renhao Li & Zheng Zeng & Xuansheng Lin & Huarui Gong & Celia Hoi-Ching Chan & Chaemin Yoon & Huiping Shuai & Deborah Tip-Yin Ho & Ivan Fa, 2023. "Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    18. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    19. Alief Moulana & Thomas Dupic & Angela M. Phillips & Jeffrey Chang & Serafina Nieves & Anne A. Roffler & Allison J. Greaney & Tyler N. Starr & Jesse D. Bloom & Michael M. Desai, 2022. "Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    20. Zhuoying Huang & Shuangfei Xu & Jiechen Liu & Linlin Wu & Jing Qiu & Nan Wang & Jia Ren & Zhi Li & Xiang Guo & Fangfang Tao & Jian Chen & Donglei Lu & Yuheng Wang & Juan Li & Xiaodong Sun & Weibing Wa, 2023. "Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-35815-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.